Comparative Study of Efficacy and Safety of Rosuvatatin 5mg Daily versus Rosuvastatin 10 mg Alternate Day in Patients with Dyslipidemia

Abstract

Background: To compare the efficacy of Rosuvastatin (5 mg) daily versus Rosuvastatin (10mg) in patients with dyslipidemia. Methods: 52-week open-label, parallel-group, comparator, prospective, and crossover trial follows a randomized process with open-label treatments. The research included 60 patients with newly diagnosed dyslipidemia who were 18–70 years old and had Serum triglycerides levels > 150 mg/dl, VLDL-C > 30 mg/dl, LDL-C>100 mg/dl, Total Cholesterol > 200 mg/dl, and HDL-C of 40 mg/dl for both men and women, according to NCEP ATP III criteria. A group of patients was divided into two. Rosuvastatin 5 mg was given to group A daily, while Rosuvastatin 10 mg was given to group B every other day for 25 weeks. The second washout period comprised 25 weeks using Rosuvastatin at 10 mg every other day, while 5 mg was administered every day to group B. Following baseline measurements, TG, LDL-C, VLDL-C, HDL, and TC were measured, as well as at the end of weeks 25 and 52. Results: As the 25th and 52nd weeks progressed, LDL-C, TG, VLDL-C, TC, and LDL/HDL were reduced more significantly in group B (13.44%, 27.27%, 37.74%, 25.86%, 25.43%, 40.74%) than in group A (33.04%, 17.79%, 15.31%, -1.79%, 37.03%, 22.22%) respectively. HDL-C concentrations in group A increased significantly (-8.68%) compared to group B (-4.9%). Conclusions: Patients with dyslipidemia treated with Rosuvastatin 10mg alternate day had a better lipid profile and reduced patient costs and pill burden than those treated with Rosuvastatin 5mg daily.